1. Home
  2. STZ vs INCY Comparison

STZ vs INCY Comparison

Compare STZ & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Constellation Brands Inc.

STZ

Constellation Brands Inc.

HOLD

Current Price

$113.43

Market Cap

19.5B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$114.20

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STZ
INCY
Founded
1945
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.5B
17.0B
IPO Year
1994
1994

Fundamental Metrics

Financial Performance
Metric
STZ
INCY
Price
$113.43
$114.20
Analyst Decision
Buy
Buy
Analyst Count
24
28
Target Price
★ $163.35
$128.48
AVG Volume (30 Days)
★ 1.8M
1.4M
Earning Date
10-06-2026
10-27-2026
Dividend Yield
★ 3.65%
N/A
EPS Growth
N/A
★ 4173.33
EPS
N/A
★ 1.47
Revenue
★ $9,139,000,000.00
$3,394,635,000.00
Revenue This Year
N/A
$15.53
Revenue Next Year
$1.75
$5.37
P/E Ratio
★ $24.93
$79.69
Revenue Growth
N/A
★ 13.67
52 Week Low
$111.54
$82.82
52 Week High
$168.60
$132.60

Technical Indicators

Market Signals
Indicator
STZ
INCY
Relative Strength Index (RSI) 27.42 32.14
Support Level N/A $110.56
Resistance Level $139.30 $119.29
Average True Range (ATR) 2.40 3.34
MACD -0.27 -1.19
Stochastic Oscillator 20.73 8.68

Price Performance

Historical Comparison
STZ
INCY

About STZ Constellation Brands Inc.

Constellation Brands is the largest provider of alcoholic beverages across the beer, wine, and spirits categories in the US, generating more than 90% of revenue from Mexican beer imports under top-selling brands such as Modelo and Corona. The rest of the business includes some remaining wine and spirits brands, categories where the company has pruned assets in recent years. With its exclusive rights tied to the Mexican beer brands effective only in the US, the firm has limited revenue exposure to international markets. Constellation owns a 10% stake in Canopy Growth, a medicinal and recreational cannabis producer in Canada, and has a 50/50 joint venture with glass manufacturer Owens-Illinois in Mexico.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: